Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $29.6350 (-2.39%) ($29.6350 - $29.6350) on Wed. Dec. 9, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.23% (three month average) | RSI | 48 | Latest Price | $29.6350(-2.39%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.5% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(60%) ARKK(56%) IBB(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.615% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-2%) UNG(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.615% (StdDev 3.23%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $28.88(2.61%) | 10 Day Moving Average | $28.88(2.61%) | 20 Day Moving Average | $29.07(1.94%) | To recent high | -4.8% | To recent low | 24.9% | Market Cap | $3.753b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |